Latest Gabather News & Updates

See the latest news and media coverage for Gabather. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Gabather

Pharmaceutical company developing CNS therapeutics

gabather.com
Headquarters
Södertälje, Sweden
Founded year
2014
Company type
Public company
Number of employees
4–10

Last updated

Latest news about Gabather

In short: Gabather progressed its GT-002 clinical program, initiating a Phase II study on schizophrenia and securing new patents for psychiatric treatments.

Company announcements

  • Gabather

    Gabather announces GT-002 study results

    Presents acute effects on psychophysiological and cognitive measures. Dated 25 November 2025. Download presentation available.

  • Gabather

    Gabather begins GT002 capsule production

    CEO announces milestone at partner facility in Spain for upcoming clinical trial. Capsules finalize this week, followed by packaging, labeling, and shipment to Denmark.

  • Gabather

    Gabather releases GT-002 EEG-fMRI study initial findings

    The findings are available for download via presentation. Date: 21 January 2025.

  • Gabather

    Gabather summarizes progress over five years

    The company describes clinical progress for GT-002, preclinical studies, EEG results, phase I/II studies and collaborations with CNSR and Karolinska Institutet.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Gabather

Track Gabather and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Gabather competitors & trending companies

Browse news for competitors to Gabather and other trending companies.